Precigen receives breakthrough therapy designation for prgn-2012 adenoverse™ immunotherapy for the treatment of recurrent respiratory papillomatosis

–  first fda breakthrough therapy designation granted for adenoverse immunotherapy platform; designation prioritizes prgn-2012 as a potential treatment for rrp – –  designation based on positive phase 1 clinical data that showed 50% of patients were "surgery-free" (complete response) after prgn-2012 treatment with a minimum follow up of 12 months post-treatment – germantown, md. , june 20, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the us food and drug administration (fda) has granted breakthrough therapy designation for the first-in-class investigational prgn-2012 adenoverse immunotherapy for the treatment of recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking